ReveraGen BioPharma Announces Start of Phase 1 Clinical Trial of VBP15 Dissociative Steroid Drug

ReveraGen BioPharma today announced the start of a Phase 1, first-in-human, clinical trial of a novel dissociative steroidal drug, VBP15, under development for Duchenne muscular dystrophy. Recruitment in the trial is underway, with the initial doses in the first volunteers having been received.

“Glucocorticoids are a mainstay of therapeutics for Duchenne muscular dystrophy, but the side effect profiles detract from patient quality of life, and VBP15 promises to retain or increase efficacy while reducing side effect profiles,” said Eric Hoffman, CEO of ReveraGen BioPharma.
More >